Cannabis Science Comments on Recent USA TODAY Article That The Obama Administration Refocuses Its Unsuccessful War On Drugs to a Public Health Fight and Speaks About the Growing Recognition of Marijuana for Medical Purposes
COLORADO SPRINGS, Colo., May 19, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that as reported in a recent article in USA TODAY the use of marijuana for Medical purposes is becoming more accepted by government officials and by the overwhelming majority of the people. According to the article, "a consensus is growing across the country that at least marijuana will someday be regulated and sold like tobacco and alcohol."
The Obama administration has recently announced the reassessment of its War On Drugs to be refocused as a Public Health Fight after 40 years, $1 Trillion dollars and thousands of lives lost. This has even brought out the support of various law enforcement personnel, including the Medford, Mass.-based Law Enforcement Against Prohibition, a group of over 13,000 police, judges, prison wardens, prosecutors and others who want to legalize and regulate all drugs. The Obama administration said it will not target marijuana dispensaries if they are compliant with state regulations.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, commented, "Cannabis Science is very pleased to see the growing support for the medical use of marijuana and looks forward to the upcoming Fall vote for South Dakota residents on whether to allow marijuana for medical practice use and the vote in November for by California voters that will decide whether to legalize marijuana. I encourage everyone in these States to vote so we can continue the increasing recognition of the benefits of medical marijuana. We are building a patient oriented company that supports the rights of the individual and opposes the use of state violence against sick and dying Americans, especially our veterans who have sacrificed so much for the freedom that they are now being denied."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science, Inc.
Dr. Robert J. Melamede, PhD., President & CEO
Mark J. Freedman